BIOFIT 2026

Entreprises exposantes référencées

Lotexpo recense actuellement 20 entreprises associées à cet événement.

• Aenova
• WEGA FRANCE SAS
• OXY’PHARM
• Véto-pharma
• AIT Molecular Diagnostics
• SYNGULON
• UNIHOLDING/ UNITHER
• CLUBSTER NHL
• Collaborative Drug Discovery
• LOWENCO A/S
• CARBOGEN AMCIS
• Vernalis (R&D) Ltd
• PhinC
• Intravacc
• MORA SAS
• Cambrex
• CER Groupe
• Rewake
• MyData-TRUST
• AseBio – Spanish Bioindustry Association

Programme de BIOFIT 2026

Le programme compte 10 sessions et 28 intervenants.

Jeudi 10 décembre 2026

• 10:00-11:00 : Investment under the microscope: 2026 review and how capital will be allocated in 2027 avec Hanno Ronte
  Looking back on 2026 investments in the early-stage landscape, experts will pause and analyse where capital went and what it says about the evolution of the life sciences market. Investors will then discuss what…
• 11:30-12:30 : From scientific excellence to competitive innovation: How Europe is strengthening its life sciences translation power avec Raoul Haschke, Gerald Law, Fabrizio Conicella, Savita Bernal et 1 autre
  Europe's science is strong. Yet, when seeing the resources allocated and cultural forces leveraged by other international giants, such as the US and China, for their economic competitiveness in life sciences, it is not…
• 14:00-15:00 : Collaborative models accelerating One Health innovation: The case of emerging infectious diseases avec Guerric Radière, Oliver Boucher, Wim van der Poel
  From a One Health perspective, bringing innovative research to real-world application cannot do without coordinated efforts between academia, start-ups and industry. Emerging infectious diseases provides a compelling…
• 16:15-17:00 : It's never too early for TPP: Best practices for young founders avec Farzad Abdi-Dezfuli, Ricardo Pacheco, Gilles Brackman, Ingrid Kelly Spillmann
  Did you draw your Target Product Profile? Because it might very well be the key to success. Positioning clearly is not rigidity, it is all about intent. And working on it as early as possible shows understanding of the…
• 17:15-18:00 : Fewer seed rounds and alternative financing strategies: They chose to collaborate with patient associations avec Poul Sørensen
  The current context of early-stage capital shortage has an impact on all stakeholders in life sciences. Alternative financing strategies are not only a nice way to move forward for innovation but for some it has become…

Vendredi 11 décembre 2026

• 10:15-11:00 : What makes an academic asset collaboration-ready for Pharma nowadays? avec Ana Gallego Roman, Claudia Andretta, Karin Agerman, Alberto Diaz Jimenez
  Pharma companies, one of the leading stakeholders of life sciences innovation, keep adapting to the evolution of the sector and the collaborations they can build according to internal strategies, pipelines and potential…
• 11:30-12:30 : From academia to industry: Scientists turned CEOs share their experience of entrepreneurship avec Gerald Law, Joana Caldeira
  Becoming a CEO is not what most scientists have in mind when starting their careers – and yet, some of them took the big step when the asset they had been working on brought enough results to be considered as market…
• 14:00-15:00 : Taking the collaboration to the next level: What triggers Pharma to bring equity in biotech companies? avec Lilian Alcaraz, Pierre Gaudeaux, Ulrich Wendt, Jan-Philipp Kruse
  Pharma is one of the main partners a biotech company can find to accelerate its innovation, and the collaboration can take many forms to align with respective needs, roadmap and pipeline, context and resources. One of…
• 14:00-15:00 : Too early for VC: best practices in building the bridge towards Series A avec Claudia Andretta, Laura Donnelly
  Early-stage is being redefined. It has become increasingly difficult to complete early-stage rounds, resulting in the emergence of a financing gap for assets and towards their maturation. What does this new context mean…
• 15:30-16:15 : How TTOs and venture builders collaborate to create more attractive start-ups avec Adam Stoten, Arezki Yaiche, Florence De Coorebyter, Pedro Lopes
  Academia is the main source of potential assets for the future of biopharma, and as such the best sourcing partner for industry players. A link between both worlds, the venture builder model continues to grow…